HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by FARID, H. A. Articles by WEIL, G. J. Search for Related Content PubMed PubMed Citation Articles by FARID, H. A. Articles by WEIL, G. J. Related Collections Lymphatic Filariasis Mosquitoes

EFFECTS OF COMBINED DIETHYLCARBAMAZINE AND ALBENDAZOLE TREATMENT OF BANCROFTIAN FILARIASIS ON PARASITE UPTAKE AND DEVELOPMENT IN CULEX PIPIENS L.

We studied effects of combined diethylcarbamazine (DEC) and albendazole (ALB) treatment on Wuchereria bancrofti microfilaria (MF) uptake and development of infective larvae (L3) in Culex pipiens. Consenting Egyptian adults with microfilaremia (MF > 300/mL) were treated with one or seven daily doses of DEC/ALB. Laboratory-reared mosquitoes were fed on subjects before and after treatment. MF uptake and infectivity (assessed by mosquito dissection) were reduced by 89.6% and 82.9%, respectively, 12 months after single-dose treatment and by 96.2% and 99.7%, respectively, after multi-dose treatment. The L3:mosquito ratio decreased by 88% to 0.082 after single-dose treatment and by 99.8% to 0.001 after multi-dose treatment. If high coverage rates can be achieved for several annual cycles, mass drug administration (MDA) with DEC/ALB has the potential to decrease transmission to unsustainable levels and eliminate filariasis in populations. Multi-dose MDA (especially in the first year) might interrupt transmission with fewer cycles than single-dose treatment.

Received July 28, 2004. Accepted for publication December 29, 2004.

Acknowledgments: We are grateful for technical assistance provided by the field research teams and laboratory staff at the Research and Training Center on Vectors of Diseases at Ain Shams University.

Financial support: This work was supported by National Institutes of Health grant AI-35855.

^* Address correspondence to Gary J. Weil, Infectious Diseases Division, Washington University School of Medicine, Box 8051, 660 S. Euclid Ave., St. Louis, MO 63110. E-mail: gweil{at}im.wustl.edu

Authors’ addresses: Hoda A. Farid, Ragaa E. Hammad, Marah M. Hassan, and Reda M. R. Ramzy, Research and Training Center on Vectors of Diseases, Faculty of Science Building, Ain Shams University, Abbassia, Cairo 11566, Egypt, Telephone and Fax, 20-2-683-9622; Maged El Setouhy, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, Egypt. Telephone and Fax, 20-2-683-9622; Gary J. Weil, Infectious Diseases Division, Box 8051, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, Telephone: 314-454-7782, Fax 314-454-5293, E-mail: gweil{at}im.wustl.edu.

This article has been cited by other articles:

				P. FISCHER, S. M. ERICKSON, K. FISCHER, J. F. FUCHS, R. U. RAO, B. M. CHRISTENSEN, and G. J. WEIL PERSISTENCE OF BRUGIA MALAYI DNA IN VECTOR AND NON-VECTOR MOSQUITOES: IMPLICATIONS FOR XENOMONITORING AND TRANSMISSION MONITORING OF LYMPHATIC FILARIASIS Am J Trop Med Hyg, March 1, 2007; 76(3): 502 - 507. [Abstract] [Full Text] [PDF]